No deviation by Efor Wins “Most Impactful Partner” Award at Validate 2026

No deviation by Efor has been named “Most Impactful Partner” at Validate 2026, an event hosted by Kneat that is dedicated to validation professionals in the life-sciences sector. The award honours our Digital Validation team’s continued leadership in replacing paper-based workflows with agile, data-centric validation strategies that accelerate compliance and time-to-market for clients worldwide.

Meeting Tomorrow’s Validation Demands Today

Life science companies face mounting regulatory requirements, complex global supply chains and increasing pressure to deliver therapies faster. Traditional, manual validation processes slow projects, create data silos and raise compliance risks. As digitalization and artificial intelligence (AI) reshape quality management, organisations need scalable, automated solutions that guarantee data integrity while freeing experts to focus on higher-value tasks. Efor addresses this challenge by embedding AI and expert know-how into every stage of validation, turning fragmented data into continuous, audit-ready insight.

Addressing Persistent Validation Challenges: Our Impact at Validate 2026

Events such as Validate 2026 are vital in the consultancy industry: they allow us to connect deeply with clients and prospects, exchange best practices, and gain insights that keep our solutions aligned with real-world challenges and at the forefront of innovation.

During the three-day event, our No deviation by Efor team presented the latest developments and AI-powered tools thatenable organizations to anticipate risks, optimize resources, and prove compliance with unprecedented speed and transparency. Via keynote interventions by Phil JARVIS and Dave O’CONNOR, our teams shared real-world case studies illustrating how digital validation allows to align C&Q and CSV activities, reduce paperwork volumes, and achieve higher right-first-time rates. Our experts also led discussions on “AI in Validation and Quality,” outlining pragmatic steps to deploy trustworthy algorithms without compromising regulatory rigor and highlighting the future roadmap for compliant, data-centric validation.

Why AI – and Responsible AI – Matter for Efor

AI is reshaping drug development and, by extension, the compliance landscape. Every new molecule triggers a vast web of protocols, traceability matrices and risk assessments. By fusing our deep regulatory and process knowledge with responsibly governed algorithms in AI-driven tools, we ensure that gaps are detected earlier, documents are generated with greater consistency, and data integrity is assured across increasingly complex manufacturing environments. This underlines our commitment to transform quality and compliance for an industry that cannot afford mistakes and requires right-first-time solutions.